Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI3020 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on IBI3020, a putative antibody-drug conjugate (ADC) targeting CEACAM5 (Apr 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI3020 | IBI-3020|IBI 3020 | CEACAM5 Antibody 12 | Limited information is currently available on IBI3020, a putative antibody-drug conjugate (ADC) targeting CEACAM5 (Apr 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06963281 | Phase I | IBI3020 | Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Recruiting | USA | 1 |